Regulatory transitions are among the most under-managed supply-continuity risks in the pharmaceutical and medical device industries. A product re-registration, a marketing-authorization transfer, a manufacturing site change, or the migration of a device from MDD to MDR under the European Union (EU) 2017/745—each creates the same quiet hazard: a window in which a product can no longer ship under its old regulatory basis but cannot yet ship under its new one.
The regulatory affairs team tracks the approval. The quality team manages the documentation. But the supply-continuity question—will patients in each market keep receiving product across the transition?—often falls into the gap between functions. And unlike a supplier delay, this risk is fully foreseeable months in advance, which makes a stockout during a planned transition one of the least forgivable failures in the industry.
The instrument for managing it is bridging stock: inventory built ahead of the transition to cover the approval gap. The hard part is not the concept. It is getting the quantity right.
Why the Flat Rule Fails
The default approach is a flat rule—“build three months of bridging stock across all markets.” It is simple, and it is almost always wrong in both directions at once.
In stable markets where the new registration will approve on time, three months of extra finished goods is working capital tied up, warehouse space consumed, and—for products with limited shelf life—a scrap-and-write-off risk if the buffer expires unused. In the markets where the approval actually slips, three months is often not enough, and the one place the rule needed to hold is the place it fails.
A flat rule treats every market as if it carried the same risk and the same demand. It does not. Bridging stock sized to an average is a buffer built for a market that doesn’t exist.
The Real Problem: Trace the Impact
Sizing bridging stock correctly requires tracing the transition’s impact through to what actually matters, and that trace runs in two directions.
Downward, through the bill of materials: a single registration, active pharmaceutical ingredient (API), or component can sit beneath multiple finished goods. A change that looks like one line item on a regulatory tracker can touch a dozen SKUs, each with its own shelf life, batch size, and lead time.
Outward, through the market structure: each finished good serves a set of markets, and each market has its own demand rate, its own approval timeline, and—this is the part that anchors the whole exercise—its own patients who depend on continuity of supply.
Follow that chain and the abstract question “how much bridging stock?” resolves into a concrete one: for this finished good, in this market, given this demand and this expected approval date, how many batches must be on the ground before the old registration lapses? The path from a single delayed excipient to a missed patient dose is not a slogan; it is the actual route you have to walk, node by node, to get the number right.
From Trace to Decision
With the trace in place, the decisions become specific rather than averaged.
Bridging quantity per market is derived from that market’s demand across the expected gap, not a flat horizon. Timing follows: the last batch produced under the old registration and the first batch released under the new one have to be sequenced per market so that shipments never fall into the gap—the last-batch-old, first-batch-new handoff that determines whether continuity holds.
And because shelf life is finite, the buffer has to be sized to cover the gap without so overshooting that it expires on the shelf. In regulated products, over-buffering is not free insurance; it is a scrap liability with a compliance trail.
A Living Picture, Not a One-Off Calculation
The most important thing I learned during a worldwide re-registration program is that none of this holds still.
Approval timelines slip. A market forecast to clear in Q2 moves to Q3, and its bridging requirement changes overnight. A single calculation at the start of the program is obsolete within weeks. What the work actually demands is a living picture—a central view that holds, per market, the current approval forecast, the derived bridging quantity, the last-old/first-new timing, and the shipments already in transit—and that updates the moment a timeline moves.
That central view is what turns a re-registration from a series of local firefights into a managed program. When a regulatory slip in one country appears, its supply consequence should be visible immediately, in stock terms, for that specific market—not discovered later when a shipment fails to cover demand.
The Universal Discipline
Bridging stock through re-registration is a vivid case, but it is one instance of a discipline the industry needs far more broadly: connect a supply-side disruption to its demand-side and patient-side impact, size the response to the actual exposure, and keep that picture current as reality shifts.
The mechanics are the same whether the trigger is a planned regulatory transition or an unplanned supplier disruption. In both cases the question is identical—trace the disruption through the bill of materials to the finished goods, markets, and patients it threatens; quantify the real exposure; and act on that, not on a flat rule or a gut feel. A device moving from MDD to MDR is the same workstream as a pharmaceutical re-registration: same mechanics, different trigger. So is a six-week slip on a critical API.
Where the Bar is Moving
The pharmaceutical industry has become good at tracking regulatory approvals and good at managing quality documentation. Where it remains uneven is in connecting those regulatory events to their supply-continuity consequences before they reach the patient.
The teams that manage transitions well are not the ones with the biggest buffers. They are the ones that can trace impact to the market level and keep that trace current—sizing continuity to real exposure rather than to a round number. As portfolios grow more complex and regulatory change accelerates—MDR, evolving variation frameworks, more frequent site and supplier changes—the flat-rule approach will keep costing money in the stable markets and failing patients in the volatile ones.
The defensible answer is the same one that applies across supply risk generally: know what a disruption actually touches, size the response to that, and never let the picture go stale.
